By Gina Shaw
Most patients who were switched from the reference product adalimumab (Humira, AbbVie) to an interchangeable biosimilar experienced clinical success, with the vast majority of patients remaining on a biosimilar three months after conversion, according to a study conducted at Brown University Health and presented in a poster (38-M) at the ASHP Pharmacy Futures 2025 meeting, in Charlotte, N.C.
JUNE 11, 2025